Merus Labs Intl Inc (MSLI) 1.26 $MSLI
Merus Labs International Inc. Announces Deemed Exercise of Special Warrants
PR Newswire - Wed May 18, 3:24PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL, NASDAQ: MSLI) is pleased to announce today the deemed exercise of the Company's 14,250,000 outstanding special warrants (the "Special Warrants" into 14,250,000 common shares (the "Common Shares". The Special Warrants were issued in connection with the bought deal financing of subscription receipts (the "Offering". The Offering was completed on March 1, 2016 and the proceeds used by the Company to fund the acquisition of the rights to the Surgestone®, Provames®, Speciafoldine®, and Tredemine® pharmaceutical products in France from Sanofi S.A.
MSLI: 1.26 (-0.01)
Merus Labs reports 2Q loss
Automated Insights - Wed May 11, 4:56PM CDT
VANCOUVER, British Columbia (AP) _ Merus Labs International Inc. (MSLI) on Wednesday reported a fiscal second-quarter loss of $2.5 million, after reporting a profit in the same period a year earlier.
MSL.TO: 1.62 (+0.01), MSLI: 1.26 (-0.01)
Merus Labs Reports Fiscal Q2 2016 Results
CNW Group - Wed May 11, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] today announced its financial results for its second quarter of fiscal year 2016.
MSLI: 1.26 (-0.01)
Merus announces re-election of directors
PR Newswire - Wed Mar 30, 8:44PM CDT
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] reported today the results of its 2016 annual general meeting of shareholders held on March 30, 2016.
MSLI: 1.26 (-0.01)
Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi
CNW Group - Mon Mar 07, 6:56AM CST
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] announced today that it has completed the previously announced acquisition of rights to Surgestone®, Provames®, Tredemine® and Speciafoldine® in France and select other markets from Sanofi. Merus also confirms that the Subscription Receipts issued on March 1, 2016 have converted into Special Warrants on a one-for-one basis in connection with the completion of the acquisition.
MSLI: 1.26 (-0.01)
Merus announces $27 million bought deal
PR Newswire - Fri Feb 19, 6:58AM CST
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] has entered into an agreement with a syndicate of underwriters (collectively, the "Underwriters" to purchase, on a bought deal private placement basis, 14,250,000 subscription receipts of the Company (the "Subscription Receipts", at a price of $1.90 per Subscription Receipt, for aggregate gross proceeds of $27,075,000 (the "Offering". The proceeds of the Subscription Receipts will be held in escrow and released to the Company upon the completion of a prospective acquisition. Each Subscription Receipt will convert into one special warrant of the Company upon completion of the acquisition (the "Special Warrants", with each Special Warrant being convertible into one common share of the Company.
MSLI: 1.26 (-0.01)
Merus completes acquisition of Elantan®, Isoket® and Deponit® rights from UCB and announces date of Q1 2016 earnings release
PR Newswire - Thu Feb 04, 5:04PM CST
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] announced today that it has completed the previously announced acquisition of rights to Elantan®, Isoket® and Deponit® in Europe and select other markets from UCB.
MSLI: 1.26 (-0.01)
IIROC Trade Resumption - MSL
CNW Group - Mon Feb 01, 2:12PM CST
Trading resumes in:
MSLI: 1.26 (-0.01)
IIROC Trade Resumption - Merus Labs International Inc.
Newsfile Corp - Mon Feb 01, 2:00PM CST
Trading resumes in:
MSLI: 1.26 (-0.01)
Merus Reaches Agreement to Acquire Three Cardiovascular Products
CNW Group - Mon Feb 01, 1:52PM CST
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] announced today that it has entered into an agreement with UCB to acquire rights to Elantan®, Isoket® and Deponit® in Europe and select other markets (the "Acquisition".
MSLI: 1.26 (-0.01)
IIROC Trading Halt - MSL
CNW Group - Mon Feb 01, 1:27PM CST
The following issues have been halted by IIROC:
MSLI: 1.26 (-0.01)
IIROC Trade Halt - Merus Labs International Inc.
Newsfile Corp - Mon Feb 01, 1:24PM CST
The following issues have been halted by IIROC:
MSLI: 1.26 (-0.01)
Merus Reports Fiscal 2015 Results and Provides Business Update
CNW Group - Mon Dec 07, 3:05PM CST
Merus Labs International Inc. ("Merus" or the "Company" [TSX: MSL, NASDAQ: MSLI] is pleased to report its financial results for fiscal year ending September 30, 2015.
MSLI: 1.26 (-0.01)
Merus Labs to Host Conference Call on Year End Results
PR Newswire - Tue Dec 01, 4:00PM CST
Merus Labs International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the Company" today announced it will release its fiscal year 2015 earnings after market close on Monday, December 7, 2015. Merus will hold a conference call at 8:30am ET on Tuesday, December 8, 2015 to discuss the results. The conference call can be accessed by dialing (888) 241-0551 and entering conference ID 95313668. International participants may dial (647) 427-3415. A replay of the call will be available for those not able to attend live by dialing (855)859-2056.
MSLI: 1.26 (-0.01)
Merus Labs International Inc. Announces Deemed Exercise of Special Warrants
PR Newswire - Wed May 18, 3:24PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
(TSX: MSL, NASDAQ: MSLI) is pleased to announce today the deemed exercise of the Company's 14,250,000 outstanding special warrants (the "Special Warrants" into 14,250,000 common shares (the "Common Shares". The Special Warrants were issued in connection with the bought deal financing of subscription receipts (the "Offering". The Offering was completed on March 1, 2016 and the proceeds used by the Company to fund the acquisition of the rights to the Surgestone®, Provames®, Speciafoldine®, and Tredemine® pharmaceutical products in France from Sanofi S.A. MSLI: 1.26 (-0.01)
Merus Labs reports 2Q loss
Automated Insights - Wed May 11, 4:56PM CDT
VANCOUVER, British Columbia (AP) _ Merus Labs International Inc. (MSLI) on Wednesday reported a fiscal second-quarter loss of $2.5 million, after reporting a profit in the same period a year earlier.
MSL.TO: 1.62 (+0.01), MSLI: 1.26 (-0.01)
Merus Labs Reports Fiscal Q2 2016 Results
CNW Group - Wed May 11, 3:00PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] today announced its financial results for its second quarter of fiscal year 2016. MSLI: 1.26 (-0.01)
Merus announces re-election of directors
PR Newswire - Wed Mar 30, 8:44PM CDT
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] reported today the results of its 2016 annual general meeting of shareholders held on March 30, 2016. MSLI: 1.26 (-0.01)
Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi
CNW Group - Mon Mar 07, 6:56AM CST
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] announced today that it has completed the previously announced acquisition of rights to Surgestone®, Provames®, Tredemine® and Speciafoldine® in France and select other markets from Sanofi. Merus also confirms that the Subscription Receipts issued on March 1, 2016 have converted into Special Warrants on a one-for-one basis in connection with the completion of the acquisition. MSLI: 1.26 (-0.01)
Merus announces $27 million bought deal
PR Newswire - Fri Feb 19, 6:58AM CST
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] has entered into an agreement with a syndicate of underwriters (collectively, the "Underwriters" to purchase, on a bought deal private placement basis, 14,250,000 subscription receipts of the Company (the "Subscription Receipts", at a price of $1.90 per Subscription Receipt, for aggregate gross proceeds of $27,075,000 (the "Offering". The proceeds of the Subscription Receipts will be held in escrow and released to the Company upon the completion of a prospective acquisition. Each Subscription Receipt will convert into one special warrant of the Company upon completion of the acquisition (the "Special Warrants", with each Special Warrant being convertible into one common share of the Company. MSLI: 1.26 (-0.01)
Merus completes acquisition of Elantan®, Isoket® and Deponit® rights from UCB and announces date of Q1 2016 earnings release
PR Newswire - Thu Feb 04, 5:04PM CST
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] announced today that it has completed the previously announced acquisition of rights to Elantan®, Isoket® and Deponit® in Europe and select other markets from UCB. MSLI: 1.26 (-0.01)
IIROC Trade Resumption - MSL
CNW Group - Mon Feb 01, 2:12PM CST
Trading resumes in:
MSLI: 1.26 (-0.01)
IIROC Trade Resumption - Merus Labs International Inc.
Newsfile Corp - Mon Feb 01, 2:00PM CST
Trading resumes in:
MSLI: 1.26 (-0.01)
Merus Reaches Agreement to Acquire Three Cardiovascular Products
CNW Group - Mon Feb 01, 1:52PM CST
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] announced today that it has entered into an agreement with UCB to acquire rights to Elantan®, Isoket® and Deponit® in Europe and select other markets (the "Acquisition". MSLI: 1.26 (-0.01)
IIROC Trading Halt - MSL
CNW Group - Mon Feb 01, 1:27PM CST
The following issues have been halted by IIROC:
MSLI: 1.26 (-0.01)
IIROC Trade Halt - Merus Labs International Inc.
Newsfile Corp - Mon Feb 01, 1:24PM CST
The following issues have been halted by IIROC:
MSLI: 1.26 (-0.01)
Merus Reports Fiscal 2015 Results and Provides Business Update
CNW Group - Mon Dec 07, 3:05PM CST
Merus Labs International Inc. ("Merus" or the "Company"
[TSX: MSL, NASDAQ: MSLI] is pleased to report its financial results for fiscal year ending September 30, 2015. MSLI: 1.26 (-0.01)
Merus Labs to Host Conference Call on Year End Results
PR Newswire - Tue Dec 01, 4:00PM CST
Merus Labs International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the Company"
today announced it will release its fiscal year 2015 earnings after market close on Monday, December 7, 2015. Merus will hold a conference call at 8:30am ET on Tuesday, December 8, 2015 to discuss the results. The conference call can be accessed by dialing (888) 241-0551 and entering conference ID 95313668. International participants may dial (647) 427-3415. A replay of the call will be available for those not able to attend live by dialing (855)859-2056. MSLI: 1.26 (-0.01)
